Patients with complete cytoreduction and HIPEC reached a median overall survival of 50 months, but early recurrence stayed common.
- Median overall survival was 50.2 months, and median disease-free survival was 9.7 months.
- Peritoneal cancer index above 10, positive lymph nodes, ASA score above 2, and right-sided primaries predicted shorter survival.
- Recurrence occurred in 71.4% of patients, most often in the peritoneum (54.8%).
- Multicenter? Not stated. Retrospective consecutive cohort of 440 patients, median follow-up 35.2 months.
The results fit selected patients with complete macroscopic cytoreduction, not all patients with colorectal peritoneal metastases. Preoperative risk scoring by peritoneal cancer index and nodal status can guide counseling, but neither induction therapy nor HIPEC regimen changed peritoneal recurrence-free survival in this cohort.
Journal Article by van Kesteren LJ, Aalbers AGJ (…) Tuynman JB et 9 al. in Ann Surg Oncol
© 2026. The Author(s).